Update of Therapeutic Clinical Trials for Amyotrophic Lateral Sclerosis.
10.14253/kjcn.2015.17.1.1
- Author:
Nam Hee KIM
1
;
Min Oh LEE
Author Information
1. Department of Neurology, College of Medicine, Dong-A University, Busan, Korea. sangmcheon@gmail.com
- Publication Type:Clinical Trial ; Review
- Keywords:
Amyotrophic lateral sclerosis;
Clinical trial;
Treatment
- MeSH:
Amyotrophic Lateral Sclerosis*;
Brain Stem;
Disease Progression;
Hope;
Motor Neuron Disease;
Motor Neurons;
Muscular Atrophy, Spinal;
Muscular Disorders, Atrophic;
Neurodegenerative Diseases;
Riluzole;
Spinal Cord;
Stem Cells
- From:Korean Journal of Clinical Neurophysiology
2015;17(1):1-16
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is characterized by progressive death of motor neurons in the cortex, brainstem, and spinal cord. Until now, many treatment strategies have been tested in ALS, but so far only Riluzole has shown efficacy of slightly slowing disease progression. The pathophysiological mechanisms underlying ALS are multifactorial, with a complex interaction between genetic factors and molecular pathways. Other motor neuron disease such as spinal muscular atrophy (SMA) and spinobulbar muscular atrophy (SBMA) are also progressive neurodegenerative disease with loss of motor neuron as ALS. This common thread of motor neuron loss has provided a target for the development of therapies for these motor neuron diseases. A better understanding of these pathogenic mechanisms and the potential pathological relationship between the various cellular processes have suggested novel therapeutic approaches, including stem cell and genetics-based strategies, providing hope for feasible treatment of ALS.
